More
Program Overview
As one of the effective means of precision medicine, Nucleic Acid-based Medicines can directly act on the target genes or target mRNA and regulate the expression of the therapeutic genes. The RNA-based medicines have greatly expanded the range of selectable targets of the innovative drugs, making the previously undruggable targets possible. In recent years, with the maturation of technologies for chemical modification, nucleic acids delivery and manufacturing, RNA-based Therapeutics is expanding rapidly with multiple products launch onto the market, showing increasingly prominent clinical advantage and market value. At the same time, with continuous research and investment in mRNA/circRNA technology both domestically and internationally, the mRNA/circRNA field has made significant progress over the past year in the context of technology development clinical application and market expansion. In addition to infectious disease vaccines, mRNA/circRNA technology has been also exploited heavily to the development of personalized cancer vaccines, In vivo CAR-T/TCR-T Therapies, protein replacement therapies, gene editing and regenerative medicine etc. In Return, the xRNA Therapeutics Development and Innovation Forum will gather leaders and scientists across RNA-based medicines innovators, leading academic centers and institutes for the discussion to facilitate the communication and partnership for the efficient Development, Delivery and Manufacturing of the Next Generation mRNA/circRNA-based Vaccines/Therapeutics and Oligonucleotide Drugs. Currently we are receiving the presentation abstracts for xRNA2027. If you'd be interested in speaking, please contact Wei Zhang at wzhang@deliver-consulting.com.
More
2026 Speaker Committee
Program Key Discussions
- Recent Progress, Frontiers and Collaboration for Nucleic Acid Therapeutics Development
- mRNA/circRNA Vaccine and Therapeutics Development, Preclinical Research and Clinical Translation
- mRNA/circRNA Process Development and Production, Analytical Characterization and Quality Control
- mRNA/circRNA Cancer Vaccine and Cancer Immunotherapy
- mRNA/circRNA-based Advanced Therapies Development (In Vivo Cell Therapy, Gene Editing, Protein Replacement and Regenerative Medicine etc.)
- Oligonucleotide Drug Development, Preclinical Research and Clinical Translation
- Oligonucleotide Drug Process Development and Production, Analytical Characterization and Quality Control
- Development and Application of Innovative Nucleic Acid Therapeutics Delivery Systems
- Investment and Collaboration in Nucleic Acid Therapeutics Industry
Who would Attend
Around 600 Executives and Scientific Managers, Professionals in the Research, Product/Process Development and Manufacturing of RNA-based Vaccines and Therapeutics (mainly including mRNA, circRNA, siRNA, ASO, saRNA etc.) are expected to attend the xRNA2026 with the main responsibilities including but not limited to:
- Executive Management and Head of R&D
- Early Discovery, Technology Development and External Innovation
- Preclinical, Clinical Development and Translational Medicine
- Process Development, Analytical and Manufacturing Sciences
- Product and Portfolio Management
- Business Development and Marketing
